- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.12. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC PARTNERSHIP WITH TSH BIOPHARM TO COMMERCIALIZE BRIMOCHOL PF IN TAIWAN REGION | 1 | HKEx | ||
| 24.11. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF PAN-90806 APPROVED BY NMPA AND MARKETING AUTHORIZATION FOR EPINASTINE ... | 2 | HKEx | ||
| 06.11. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTION AGREEMENT WITH PT FERRON TO COMMERCIALIZE BRIMOCHOL PF IN INDONESIA | - | HKEx | ||
| 19.09. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 19.09. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 19.09. | ZHAOKE OPHTH-B (06622): 2025 INTERIM REPORT | - | HKEx | ||
| 08.09. | ZHAOKE OPHTH-B (06622): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
| 28.08. | ZHAOKE OPHTH-B (06622): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | - | HKEx | ||
| 14.08. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | - | HKEx | ||
| 04.08. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - MEDICAL DEVICE REGISTRATION CERTIFICATE OBTAINED FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR ... | 1 | HKEx | ||
| 30.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ORPHAN DRUG DESIGNATION RECEIVED FROM THE U.S FDA FOR MELPHALAN TARGETING PEDIATRIC RETINOBLASTOMA | 4 | HKEx | ||
| 15.07. | Zhaoke Ophthalmology, Fareva Sign Memorandum of Agreement | 1 | Contract Pharma | ||
| 09.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF NEW DRUG APPLICATION FOR NVK002 (ATROPINE SULPHATE EYE DROPS 0.02%) FOR THE TREATMENT ... | 1 | HKEx | ||
| 02.07. | ZHAOKE OPHTH-B (06622): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 02.07. | ZHAOKE OPHTH-B (06622): CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 30.06. | ZHAOKE OPHTH-B (06622): NOMINATION COMMITTEE - TERMS OF REFERENCE | 1 | HKEx | ||
| 18.02. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 18.02.2025 | 1.172 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.02.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.02.2025
Aktien
1 GB00BN0VZ646 Ferrari Group PLC
2... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,396 | -4,82 % | BioNTech SE: BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld | BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen... ► Artikel lesen | |
| QIAGEN | 39,120 | +1,76 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,11 | -0,30 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,750 | +0,43 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| BIONTECH | 79,05 | 0,00 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| JYONG BIOTECH | 6,330 | +99,37 % | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,495 | +5,39 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| EVOTEC | 5,226 | +1,59 % | Eilmeldung am Abend: EVOTEC SE - jetzt wird's brisant! | ||
| IMMUNOME | 22,000 | +2,80 % | Immunome-Aktie fällt nach Ankündigung einer Kapitalerhöhung über 400 Mio. US-Dollar | ||
| OLEMA PHARMACEUTICALS | 28,550 | +2,59 % | From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 64,30 | -0,99 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 53,30 | +4,24 % | Vera Therapeutics stock price target raised to $66 by BofA Securities | ||
| BEAM THERAPEUTICS | 28,140 | +5,91 % | BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy | ||
| SUMMIT THERAPEUTICS | 18,015 | +1,09 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| KYMERA THERAPEUTICS | 84,96 | +1,15 % | Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital |
Das Unternehmen ZHAOKE OPHTHALMOLOGY LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,302 Euro und damit -3,21 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHAOKE OPHTHALMOLOGY LTD finden Sie auf Wallstreet Online.